1) Operational Highlights and Strategic Developments - UHS experienced a rebound in acute care and behavioral health volumes, consistent with recent trends. - The company added 177 licensed beds across three hospitals, marking a 2.5% increase in same facility bed capacity. - The Alan B. Miller Medical Center in Palm Beach Gardens, Florida, opened in May and received Joint Commission accreditation in July. - UHS is progressing with the integration of the Talkspace acquisition, expected to close in mid-August, enhancing their outpatient behavioral health services.

2) Financial Performance and Segment Results - Adjusted EPS for Q2 2026 was $5.98, a 12% YoY increase; adjusted EBITDA less NCI was $678 million, up 5% YoY. - Acute care adjusted admissions increased by 2.9% YoY, while same facility acute care net revenue rose by 8.2%. - Behavioral health segment revenue grew by 7.4%, with EBITDA increasing by 9.0%. - Year-to-date, UHS fine-tuned its volume guidance for acute care to 1.5%-2.5% and for behavioral health to 1.0%-2.0%.

3) Challenges and Headwinds - UHS faced increased professional and general liability reserves, impacting Q2 results by approximately $28 million. - The San Antonio behavioral facility is undergoing recertification, leading to anticipated operating losses of $5 million to $10 million per quarter until 2027. - Exchange volumes declined by about 15% YoY, with a corresponding increase in self-pay volumes, contributing to a projected $85 million pretax impact for the year.

4) Capital Allocation and Share Repurchase Activity - UHS repurchased $320 million of shares in Q2, significantly up from $127 million in Q1 2026, capitalizing on share price dislocation. - The company maintains a strong balance sheet with $978 million in repurchase authorization remaining. - Capital expenditures for Q2 totaled $228 million, reflecting investments in new facilities and capacity expansions.

5) Guidance and Outlook - UHS updated its 2026 guidance to reflect approximately 7% revenue growth, 3% EBITDA less NCI growth, and 6% EPS growth at the midpoint. - The adjusted EBITDA less NCI forecast is now in the range of $2.61 billion to $2.72 billion, reflecting a $50 million decrease from prior expectations. - The company remains optimistic about long-term growth driven by strategic investments and market demand, despite current challenges.

Bottom line: UHS is navigating a complex environment with strong operational performance and strategic expansions, but faces headwinds from increased liabilities and changing payer dynamics. The company’s proactive capital allocation and share repurchase strategy, alongside a solid long-term outlook, position it favorably for shareholders.